Autologous hybrid TREG/Th2 cell therapy (Rapa Therapeutics)

N/A

Report date: 2023/04/28 20:00:32

Base Information

Drug NameAutologous hybrid TREG/Th2 cell therapy (Rapa Therapeutics)

Drug Alias NameRAPA-501 cellsRAPA-501 Autologous T cellsRAPA-501

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs/Th2 cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Amyotrophic Lateral Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesRapa Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesRapa Therapeutics Llc

Inactive CompaniesN/A

Active IndicationsAmyotrophic Lateral Sclerosis

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A